Opinion|Videos|January 5, 2024
Adverse Events Seen With JAK Inhibitors for Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Breast Cancer Treatments Awaiting FDA Decisions: 4 to Watch
2
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer
3
What Breast Cancer Survivors Should Know About Weight Loss and Long-Term Health
4
6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You
5